XERS (NASDAQ) - Xeris Pharmaceuticals Inc

Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US98422E1038
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Web URL: https://www.xerispharma.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for XERS (NASDAQ) - Xeris Pharmaceuticals Inc
Market Cap. 387m USD
GiC Sector Health Care
GiC Industry Pharmaceuticals
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2018-06-21


Fundamental -3.59
Dividend -
Performance 5y -4.76
Performance TTM 10.00
Relative Performance 9.27
Analysts 4.50
Price / Fair Price TR 1.56
Price / Fair Price DCF todo


Growth TTM 40.48%
CAGR 5y -32.16%
CAGR / Mean Drawdown 5y -0.43
Sharpe Ratio TTM 0.48
Alpha vs SP500 TTM 30.71
Beta vs SP500 5y weekly 1.60
CAPM 13.12%
Average Daily Range % 7.47%
Volatility GJR Garch 1y 70.91%
Max Drawdown 5y 96%
Mean Drawdown 5y 75.6%
Price / SMA 50 21.9%
Price / SMA 200 78.79%
Current Volume 1406.8k
Average Volume 1253.9k


Rate TTM 0.00
Yield TTM 0.00%
Div. CAGR 5y 0.00%
Consistency of Dividends all time 0.0%